Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Roche Holding’s updated fair value estimate has shifted from CHF 358.45 to CHF 363.47, a modest move that keeps the focus on how the story is evolving rather than on a sweeping reset. That small change sits alongside a split in recent analyst views, with some pointing to potential upside and others holding back due to pipeline timing and trial questions. As you read on, you will see how these differing opinions shape the narrative and what to watch to stay on top of it.
Stay updated as the Fair Value for Roche Holding shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Roche Holding.
Barclays upgraded Roche to Overweight from Equal Weight with a CHF 390 price target, highlighting what it calls an attractive setup for 2026 clinical catalysts and an undemanding valuation.
Goldman Sachs upgraded Roche to Neutral on what it describes as improved growth potential, signaling more constructive sentiment after previous caution.
Berenberg raised its price target to CHF 340 from CHF 320 while keeping a Hold rating, reflecting a more supportive stance on the shares despite only a moderate adjustment.
HSBC, while trimming its price target to CHF 365 from CHF 385, suggested healthcare could appeal to investors given macro and geopolitical risks and lower exposure to AI related disruption.
BNP Paribas downgraded Roche to Neutral from Outperform and reduced its estimates after recent pipeline updates, pointing out that major clinical updates are not expected until 2027.
JPMorgan lowered its price target to CHF 325 from CHF 350 and kept a Neutral rating, underscoring a more cautious stance on valuation and execution while key trials and readouts remain further out.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
SWX:ROG 1-Year Stock Price Chart
We’ve flagged 1 risk for Roche Holding. See which could impact your investment.
The U.S. FDA classified Roche’s Ionify steroid assays on the cobas Mass Spec solution as CLIA moderate complexity. This allows more routine clinical labs to run mass spectrometry based testing.
Roche reported mixed phase III persevERA data in ER positive, HER2 negative metastatic breast cancer, with no statistically significant progression free survival benefit but a numerical improvement versus letrozole plus palbociclib. Development of giredestrant is continuing.
Roche and Genentech, together with Zealand, released positive Phase II ZUPREME 1 results for petrelintide in obesity. The study showed up to 10.7% mean weight loss at 28 weeks versus 1.7% with placebo and a favorable tolerability profile.
Phase II data for CT 388, a dual GLP 1/GIP agonist for obesity, showed placebo adjusted weight loss of 22.5% at 48 weeks on the efficacy estimand and low discontinuation rates. Further data are planned for presentation at a medical congress, and the Chairman also flagged potential future U.S. tariffs on the diagnostics division after a 150 day grace period.
Story Continues
Fair value has moved from CHF 358.45 to CHF 363.47, representing a small upward adjustment to the model output.
Revenue growth assumptions have been reduced from 2.71% to 2.18% in CHF terms.
The assumed net profit margin has moved from 26.05% to 25.63% on CHF revenues.
The future P/E multiple has risen from 17.84x to 18.67x, which contributes more to the updated fair value.
The discount rate remains unchanged at 3.91%, so rate and risk assumptions are the same.
Narratives connect Roche Holding’s clinical, commercial, and policy story to a set of financial assumptions and a fair value estimate. They update as new trial results, pricing changes, or regulatory decisions come through, so you can see how the investment case evolves over time.
Head over to the Simply Wall St Community and follow the Narrative on Roche Holding to stay up to date on:
How expanding diagnostics platforms, AI tools, and high value biologics in oncology, immunology, and neurology feed into future revenue and margin assumptions.
What analysts are incorporating for obesity assets like petrelintide and CT 388, the targeted cost savings of CHF 3b by 2030, and a shift toward newer, less patent sensitive medicines.
Key pressure points, including China pricing reforms, upcoming patent expiries on major biologics, biosimilar competition, and the impact of healthcare cost controls on profitability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ROG.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com